FDA Accepts SHINKEI Therapeutics Investigational New Drug Application for MR-301 for Traumatic Brain Injury PRINCETON, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- SHINKEI Therapeutics., a clinical stage pharmaceutical company focused on the development of therapeutic drugs for the treatment of Central Nervous...

シンケイ･セラピューティクス、情動調節障害治療の新剤形MR-201について新薬臨床試験開始届の提出を発表 ニュージャージー州プリンストン発, Aug. 21, 2019 (GLOBE NEWSWIRE) -- 臨床病期向け治療薬の会社として、中枢神経系 (Central Nervous System: CNS) 障害の治療薬開発に特化するシンケイ･セラピューティクス (SHINKEI Therapeutics) は本日、臨床試験用の新薬 (Investigational New Drug:...

SHINKEI Therapeutics宣布提交试验性新药申请MR-201——假性延髓情绪治疗的新型制剂 新泽西州普林斯顿, Aug. 21, 2019 (GLOBE NEWSWIRE) -- SHINKEI Therapeutics公司是一家专注研发中枢神经系统（CNS）疾病治疗药物的临床阶段制药公司，它于今日宣布向美国食品药品监督管理局提交一种试验性新药（“IND”）申请MR-201，一种治疗假性延髓情绪的新型制剂。 ...

SHINKEI Therapeutics Announces Investigational New Drug Application Submission for MR-201, a Novel Dosage Form for Treatment of Pseudobulbar Affect PRINCETON, N.J., Aug. 21, 2019 (GLOBE NEWSWIRE) -- SHINKEI Therapeutics, a clinical stage pharmaceutical company focused on the development of drugs for the treatment of Central Nervous System (CNS)...